For children between the ages of 5 and 16 with asthma that is not being effectively managed with a combination of a short-acting beta agonist (SABA), low-dose inhaled corticosteroids (ICS), and a leukotriene receptor antagonist, it is recommended to add a long-acting beta agonist (LABA) to the treatment plan and discontinue the use of the leukotriene receptor antagonist.

Managing Asthma in Children: NICE Guidelines

The National Institute for Health and Care Excellence (NICE) released guidelines in 2017 for the management of asthma in children aged 5-16. These guidelines follow a stepwise approach, with treatment options based on the severity of the child’s symptoms. For newly-diagnosed asthma, short-acting beta agonists (SABA) are recommended. If symptoms persist or worsen, a combination of SABA and paediatric low-dose inhaled corticosteroids (ICS) may be used. Leukotriene receptor antagonists (LTRA) and long-acting beta agonists (LABA) may also be added to the treatment plan.

For children under 5 years old, clinical judgement plays a greater role in diagnosis and treatment. The stepwise approach for this age group includes an 8-week trial of paediatric moderate-dose ICS for newly-diagnosed asthma or uncontrolled symptoms. If symptoms persist, a combination of SABA and paediatric low-dose ICS with LTRA may be used. If symptoms still persist, referral to a paediatric asthma specialist is recommended.

It is important to note that NICE doesn’t recommend changing treatment for patients with well-controlled asthma simply to adhere to the latest guidelines. Additionally, maintenance and reliever therapy (MART) may be used for combined ICS and LABA treatment, but only for LABAs with a fast-acting component. The definitions for low, moderate, and high-dose ICS have also changed, with different definitions for children and adults.

Benzodiazepine withdrawal syndrome doesn’t include hypothermia as a symptom.

Benzodiazepines are drugs that enhance the effect of the neurotransmitter GABA, which has an inhibitory effect on the brain. This makes them useful for a variety of purposes, including sedation, anxiety relief, muscle relaxation, and as anticonvulsants. However, patients can develop a tolerance and dependence on these drugs, so they should only be prescribed for short periods of time. When withdrawing from benzodiazepines, it is important to do so gradually, reducing the dose every few weeks. If patients withdraw too quickly, they may experience benzodiazepine withdrawal syndrome, which can cause a range of symptoms including insomnia, anxiety, and seizures. Other drugs, such as barbiturates, work in a similar way but have different effects on the duration or frequency of chloride channel opening.

Managing Depression in Children: A Tiered Approach

In managing moderate to severe depression in children, the first step is to refer them for assessment to tier 2-3 CAMHS. The three tiers of CAMHS cover practitioners who are not mental health specialists and work in universal services (Tier 1), CAMHS specialists working in community and primary care (Tier 2), and multidisciplinary teams delivering specialist services in community mental health clinics (Tier 3).

For mild depression, Tier 1 management is sufficient. However, for moderate to severe depression, specific psychological therapy in the form of individual CBT, interpersonal therapy, or shorter-term family therapy is the first-line treatment. If the depression is unresponsive to psychological therapy after four to six sessions, a multidisciplinary review should be conducted, and alternative or additional psychological therapies and medication should be considered.

In summary, managing depression in children requires a tiered approach that involves referral to the appropriate CAMHS tier and the use of specific psychological therapies. It is essential to monitor the child’s response to treatment and adjust the management plan accordingly.

Understanding Porphyria Cutanea Tarda

Porphyria cutanea tarda is a type of hepatic porphyria that is commonly inherited due to a defect in uroporphyrinogen decarboxylase. However, it can also be caused by liver damage from factors such as alcohol, hepatitis C, or estrogen. The condition is characterized by a rash that is sensitive to sunlight, with blistering and skin fragility on the face and hands being the most common features. Other symptoms include hypertrichosis and hyperpigmentation.

To diagnose porphyria cutanea tarda, doctors typically look for elevated levels of uroporphyrinogen in the urine, as well as pink fluorescence under a Wood’s lamp. Additionally, serum iron ferritin levels are used to guide therapy.

Treatment for porphyria cutanea tarda typically involves the use of chloroquine or venesection. Venesection is preferred if the iron ferritin level is above 600 ng/ml. With proper management, individuals with porphyria cutanea tarda can lead normal lives.

A provoked pulmonary embolism, which occurred after surgery and immobilisation in a middle-aged man, typically requires treatment for at least 3 months. However, the duration of treatment may need to be extended or specialist referral may be necessary depending on the patient’s leg and respiratory symptoms. Indefinite anticoagulation is not recommended unless the problem is recurrent or the patient has thrombophilia. Referral to a haematologist is also not necessary unless the treatment is unsuccessful or the patient experiences further thrombosis issues. Anticoagulation for 6 months may be considered for unprovoked pulmonary embolism, but in this case, the patient’s condition was provoked by surgery and immobilisation.

Management of Pulmonary Embolism

Pulmonary embolism (PE) is a serious condition that requires prompt management. The National Institute for Health and Care Excellence (NICE) updated their guidelines on the management of venous thromboembolism (VTE) in 2020, with some key changes. One of the significant changes is the recommendation to use direct oral anticoagulants (DOACs) as the first-line treatment for most people with VTE, including those with active cancer. Another change is the increasing use of outpatient treatment for low-risk PE patients, determined by a validated risk stratification tool.

Anticoagulant therapy is the cornerstone of VTE management. The guidelines recommend using apixaban or rivaroxaban as the first-line treatment for PE, followed by LMWH, dabigatran, edoxaban, or a vitamin K antagonist (VKA) if necessary. For patients with active cancer, DOACs are now recommended instead of LMWH. The length of anticoagulation depends on whether the VTE was provoked or unprovoked, with treatment typically lasting for at least three months. Patients with unprovoked VTE may continue treatment for up to six months, depending on their risk of recurrence and bleeding.

In cases of haemodynamic instability, thrombolysis is recommended as the first-line treatment for massive PE with circulatory failure. Other invasive approaches may also be considered where appropriate facilities exist. Patients who have repeat pulmonary embolisms, despite adequate anticoagulation, may be considered for inferior vena cava (IVC) filters. However, the evidence base for IVC filter use is weak, and further studies are needed.

BNF Prescribing in Children

When prescribing medication for children, it is important to consider their weight and calculate the appropriate dosage based on their weight and the recommended dose per kilogram. For example, if a child weighs 8 kg and the recommended dose is 12.5 mg/kg BD, the correct dosage would be 100 mg BD. It is also important to consider the concentration of the medication, such as a sodium valproate solution that contains 200 mg in 5 ml. By calculating the appropriate dosage, healthcare professionals can ensure that children receive safe and effective treatment.

If there is suspicion of scarlet fever, it is important to inform the local HPT without waiting for laboratory confirmation, as detecting outbreaks quickly is a priority for Public Health England. Clinical suspicion of a notifiable infection is sufficient for reporting purposes since 1968.

Scarlet fever is a condition caused by erythrogenic toxins produced by Group A haemolytic streptococci, usually Streptococcus pyogenes. It is more common in children aged 2-6 years, with the highest incidence at 4 years. The disease is spread through respiratory droplets or direct contact with nose and throat discharges. The incubation period is 2-4 days, and symptoms include fever, malaise, headache, sore throat, ‘strawberry’ tongue, and a rash that appears first on the torso and spares the palms and soles. Scarlet fever is usually a mild illness, but it may be complicated by otitis media, rheumatic fever, acute glomerulonephritis, or rare invasive complications.

To diagnose scarlet fever, a throat swab is usually taken, but antibiotic treatment should be started immediately, rather than waiting for the results. Management involves oral penicillin V for ten days, while patients with a penicillin allergy should be given azithromycin. Children can return to school 24 hours after starting antibiotics, and scarlet fever is a notifiable disease. Desquamation occurs later in the course of the illness, particularly around the fingers and toes. The rash is often described as having a rough ‘sandpaper’ texture, and children often have a flushed appearance with circumoral pallor. Invasive complications such as bacteraemia, meningitis, and necrotizing fasciitis are rare but may present acutely with life-threatening illness.

If a couple has a history of neural tube defects (NTDs), either partner has a NTD, or they have a family history of NTDs, they are at high risk of conceiving a child with this condition. Additionally, if the woman has coeliac disease, diabetes, thalassaemia trait, or is taking antiepileptic drugs, the risk is also increased. However, being obese (with a BMI of 30 kg/m2 or more) is not a risk factor for NTDs and may actually be protective. On the other hand, advancing maternal age is a known risk factor for Down’s syndrome, while maternal rubella can lead to multiple congenital malformations and mental retardation in the child.

Folic Acid: Importance, Deficiency, and Prevention

Folic acid is a vital nutrient that is converted to tetrahydrofolate (THF) in the body. THF plays a crucial role in transferring 1-carbon units to essential substrates involved in DNA and RNA synthesis. Green, leafy vegetables are a good source of folic acid. However, certain medications like phenytoin and methotrexate, pregnancy, and alcohol excess can cause folic acid deficiency. This deficiency can lead to macrocytic, megaloblastic anemia and neural tube defects.

To prevent neural tube defects during pregnancy, all women should take 400mcg of folic acid until the 12th week of pregnancy. Women at higher risk of conceiving a child with a neural tube defect should take 5mg of folic acid from before conception until the 12th week of pregnancy. Women are considered higher risk if either partner has a neural tube defect, they have had a previous pregnancy affected by a neural tube defect, or they have a family history of a neural tube defect. Additionally, women with antiepileptic drugs or coeliac disease, diabetes, or thalassaemia trait, and those who are obese (BMI of 30 kg/m2 or more) are also at higher risk and should take the higher dose of folic acid.

The RCGP curriculum includes public health education, which involves promoting health and preventing disease. GPs are required to have an understanding of the surveillance systems they are involved in. The Saving Lives, Improving Mothers’ Care report is an example of a Confidential Enquiry, which replaces the previous Confidential Enquiry into Maternal and Child Health (CEMACH), also known as Why Mothers Die. The purpose of a Confidential Enquiry is to investigate morbidity and mortality cases to identify areas of practice that need improvement. The details of each individual case are kept confidential and not published. GPs are often involved in providing information about maternal deaths to the team responsible for producing the Saving Lives, Improving Mothers’ Care report. Expert reviewers gather and assess information from various healthcare professionals involved in the patient’s care, including GPs.

Understanding Confidential Enquiries

A confidential enquiry is a process of investigating morbidity and mortality cases to identify areas of practice that need improvement. The purpose of this investigation is to ensure that healthcare providers are delivering the best possible care to their patients. The confidentiality of each case is maintained, and no details are published to protect the privacy of the individuals involved.

During a confidential enquiry, healthcare providers review cases of morbidity and mortality to identify any shortcomings in their practice. This process helps to identify areas where improvements can be made to prevent similar incidents from occurring in the future. The confidentiality of each case is essential to encourage healthcare providers to participate in the process without fear of retribution or legal action.

In conclusion, confidential enquiries are an essential tool for improving healthcare practices. By identifying areas of improvement, healthcare providers can work to prevent similar incidents from occurring in the future. The confidentiality of each case is critical to ensure that healthcare providers feel comfortable participating in the process and that the privacy of the individuals involved is protected.

The recommended first-line treatment for scabies is the application of permethrin cream to all skin, including the scalp, which should be left on for 12 hours before rinsing off. This treatment should be repeated after 7 days. Malathion is a second-line treatment that should be rinsed off after 24 hours. Steroids may be used by dermatologists in cases of resistant scabies or scabies pruritus, but only under specialist guidance. Salt water bathing is not recommended as a treatment for scabies. Mupirocin cream is used to eliminate MRSA in asymptomatic hospital inpatients.

Scabies: Causes, Symptoms, and Treatment

Scabies is a skin condition caused by the mite Sarcoptes scabiei, which is spread through prolonged skin contact. It is most commonly seen in children and young adults. The mite burrows into the skin, laying its eggs in the outermost layer. The resulting intense itching is due to a delayed hypersensitivity reaction to the mites and eggs, which occurs about a month after infection. Symptoms include widespread itching, linear burrows on the fingers and wrists, and secondary features such as excoriation and infection.

The first-line treatment for scabies is permethrin 5%, followed by malathion 0.5% if necessary. Patients should be advised to avoid close physical contact until treatment is complete and to treat all household and close contacts, even if asymptomatic. Clothing, bedding, and towels should be laundered, ironed, or tumble-dried on the first day of treatment to kill off mites. The insecticide should be applied to all areas, including the face and scalp, and left on for 8-12 hours for permethrin or 24 hours for malathion before washing off. Treatment should be repeated after 7 days.

Crusted scabies, also known as Norwegian scabies, is a severe form of the condition seen in patients with suppressed immunity, particularly those with HIV. The skin is covered in hundreds of thousands of mites, and isolation is essential. Ivermectin is the treatment of choice.

Dealing with Uncertainty in Long Covid Management

Dealing with uncertainty can be challenging for both patients and clinicians, especially in a rapidly evolving field like long covid management. It is unlikely that candidates will be tested on precise details that may change between question setting and the exam. Instead, questions may focus on the management of conditions that are poorly understood or the more reliable do not dos.

One important point to note is that there is no reliable evidence to support prescribing steroids or antivirals for suspected long covid, especially by a generalist. At least 10% of people with acute covid-19 may experience symptoms that persist for months, and recovery timescales can vary. There is no set date by which patients should have settled, and there is no evidence that patients are infectious at this stage of the disease.

It is also important to consider psychological illness as a potential factor in long covid management. Clinicians should keep an open mind about this when evaluating patients, while also being alert to alternative diagnoses and investigating where appropriate. By staying informed and adaptable, clinicians can better navigate the uncertainties of long covid management.

As per the NICE 2017 guidelines, if a patient with asthma is not effectively managed with a SABA + ICS, their treatment plan should include the addition of a LTRA instead of a LABA. In this case, since the patient is already taking a short-acting beta-agonist and a low-dose inhaled corticosteroid, the recommended course of action would be to offer them an oral leukotriene receptor antagonist. This is in contrast to the previous BTS guidance which would have suggested the use of a long-acting beta-agonist in such a scenario.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 British Thoracic Society (BTS) guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist, not a LABA. NICE doesn’t follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. It should be noted that NICE doesn’t recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance.

The steps for managing asthma in adults are as follows: for newly-diagnosed asthma, a short-acting beta agonist (SABA) is recommended. If the patient is not controlled on the previous step or has symptoms >= 3/week or night-time waking, a SABA + low-dose inhaled corticosteroid (ICS) is recommended. For step 3, a SABA + low-dose ICS + leukotriene receptor antagonist (LTRA) is recommended. Step 4 involves a SABA + low-dose ICS + long-acting beta agonist (LABA), and LTRA should be continued depending on the patient’s response. Step 5 involves a SABA +/- LTRA, and switching ICS/LABA for a maintenance and reliever therapy (MART) that includes a low-dose ICS. Step 6 involves a SABA +/- LTRA + medium-dose ICS MART, or changing back to a fixed-dose of a moderate-dose ICS and a separate LABA. Step 7 involves a SABA +/- LTRA + one of the following options: increasing ICS to high-dose (only as part of a fixed-dose regime, not as a MART), a trial of an additional drug (for example, a long-acting muscarinic receptor antagonist or theophylline), or seeking advice from a healthcare professional with expertise in asthma.

It is important to note that the definitions of what constitutes a low, moderate, or high-dose ICS have changed. For adults, <= 400 micrograms budesonide or equivalent is considered a low dose, 400 micrograms - 800 micrograms budesonide or equivalent is a moderate dose, and > 800 micrograms budes

Emergency Treatment in Primary Care

Potentially life-threatening situations are rare in primary care, but prompt action by a vigilant GP can save lives. Both NICE/CKS and the BNF are reference sources for the AKT exam, and they recommend admitting the person to the hospital as an emergency by calling 999. Treatment should not delay transfer to the hospital, and a single dose of parenteral benzylpenicillin should be administered as soon as possible, provided that it doesn’t delay urgent transfer to the hospital.

Emergency treatment is a crucial topic for the exam, and candidates have performed poorly in the past. It is essential to have benzylpenicillin, a suitable diluent, needles and syringes, and to be familiar with the correct doses for the age range. It is also crucial to ensure that the medicines in the emergency drug bag have not expired and to know who pays for them. More general GP admin and management issues appear to be a weak area for Registrars. If you are unsure about any of the questions posed, ask your trainer who pays for emergency drugs and whether the cost can be claimed back.

The preferred diluent in syringe drivers is ‘water for injection’.

When a patient in palliative care is unable to take oral medication due to various reasons such as nausea, dysphagia, intestinal obstruction, weakness or coma, a syringe driver should be considered. In the UK, there are two main types of syringe drivers: Graseby MS16A (blue) and Graseby MS26 (green). The delivery rate for the former is given in mm per hour, while the latter is given in mm per 24 hours.

Most drugs are compatible with water for injection, but for certain drugs such as granisetron, ketamine, ketorolac, octreotide, and ondansetron, sodium chloride 0.9% is recommended. Commonly used drugs for various symptoms include cyclizine, levomepromazine, haloperidol, metoclopramide for nausea and vomiting, hyoscine hydrobromide, hyoscine butylbromide, or glycopyrronium bromide for respiratory secretions/bowel colic, midazolam, haloperidol, levomepromazine for agitation/restlessness, and diamorphine as the preferred opioid for pain.

When mixing drugs, diamorphine is compatible with most other drugs used, including dexamethasone, haloperidol, hyoscine butylbromide, hyoscine hydrobromide, levomepromazine, metoclopramide, and midazolam. However, cyclizine may precipitate with diamorphine when given at higher doses, and it is incompatible with a number of drugs such as clonidine, dexamethasone, hyoscine butylbromide (occasional), ketamine, ketorolac, metoclopramide, midazolam, octreotide, and sodium chloride 0.9%.

Heberden’s Nodules: Bony Swellings in Osteoarthritis

Heberden’s nodules are bony swellings that typically develop around the distal interphalangeal joints, particularly in the second and third fingers. These nodules are caused by calcific spurs of the articular cartilage at the base of the terminal phalanges in osteoarthritis. This condition is more common in females and usually occurs in middle age. Heberden’s nodules can cause pain and stiffness in the affected joints, and may limit hand function. Proper management of osteoarthritis can help alleviate symptoms and improve quality of life.

Calculating the Number Needed to Treat (NNT) for Vertigo Treatment

To determine the effectiveness of a vertigo treatment, we can calculate the Number Needed to Treat (NNT). This is done by first calculating the Absolute Risk Reduction (ARR), which is the difference between the Control Event Rate (CER) and the Experimental Event Rate (EER). For example, if 55 out of 100 control patients failed to have a resolution of vertigo, and 30 out of 100 treatment patients failed to improve, the ARR would be 0.55 – 0.30 = 0.25. To find the NNT, we simply take the reciprocal of the ARR, which in this case would be 1/0.25 = 4. This means that for every 4 patients treated with the vertigo treatment, one patient will have a resolution of their vertigo.

When a person develops a high-stepping gait, it is often a compensatory mechanism for foot drop. If foot drop is found on only one side, it is likely that there is a lesion in the common peroneal nerve. However, if foot drop is present on both sides, it is more probable that the cause is peripheral neuropathy.

Peripheral neuropathy is a condition that can be categorized based on whether it predominantly causes a motor or sensory loss. When the motor function is affected, conditions such as Guillain-Barre syndrome, porphyria, lead poisoning, hereditary sensorimotor neuropathies (HSMN) like Charcot-Marie-Tooth, chronic inflammatory demyelinating polyneuropathy (CIDP), and diphtheria may be the cause. On the other hand, when the sensory function is affected, conditions such as diabetes, uremia, leprosy, alcoholism, vitamin B12 deficiency, and amyloidosis may be the cause.

Alcoholic neuropathy is a type of peripheral neuropathy that is caused by both direct toxic effects and reduced absorption of B vitamins. Typically, sensory symptoms present before motor symptoms. Vitamin B12 deficiency can lead to subacute combined degeneration of the spinal cord, where the dorsal column is usually affected first, causing joint position and vibration issues before distal paraesthesia. It is important to identify the underlying cause of peripheral neuropathy to provide appropriate treatment and management.

The patient’s symptoms suggest a diagnosis of achalasia, which is characterized by the failure of the lower oesophageal sphincter to relax, leading to a functional stricture. This can cause substernal cramps, regurgitation, and pulmonary aspiration due to the retention of food and saliva in the oesophagus, resulting in a nocturnal cough. Diagnosis is made using a barium swallow, and treatment involves endoscopic balloon dilation or cardiomyotomy. Barrett’s oesophagus, motor neurone disease, oesophageal carcinoma, and pharyngeal pouch are less likely diagnoses based on the patient’s age, symptoms, and medical history.

Rheumatic fever is a condition that occurs as a result of an immune response to a recent Streptococcus pyogenes infection, typically occurring 2-4 weeks after the initial infection. The pathogenesis of rheumatic fever involves the activation of the innate immune system, leading to antigen presentation to T cells. B and T cells then produce IgG and IgM antibodies, and CD4+ T cells are activated. This immune response is thought to be cross-reactive, mediated by molecular mimicry, where antibodies against M protein cross-react with myosin and the smooth muscle of arteries. This response leads to the clinical features of rheumatic fever, including Aschoff bodies, which are granulomatous nodules found in rheumatic heart fever.

To diagnose rheumatic fever, evidence of recent streptococcal infection must be present, along with 2 major criteria or 1 major criterion and 2 minor criteria. Major criteria include erythema marginatum, Sydenham’s chorea, polyarthritis, carditis and valvulitis, and subcutaneous nodules. Minor criteria include raised ESR or CRP, pyrexia, arthralgia, and prolonged PR interval.

Management of rheumatic fever involves antibiotics, typically oral penicillin V, as well as anti-inflammatories such as NSAIDs as first-line treatment. Any complications that develop, such as heart failure, should also be treated. It is important to diagnose and treat rheumatic fever promptly to prevent long-term complications such as rheumatic heart disease.

Individuals with sickle cell disease should be administered the pneumococcal polysaccharide vaccine every 5 years to prevent pneumococcal infections, as they are at a heightened risk due to the hypofunction of their spleen caused by recurrent splenic infarction. Children should receive their first vaccine at 2 years of age, followed by subsequent doses every 5 years.

Managing Sickle-Cell Anaemia

Sickle-cell anaemia is a genetic blood disorder that causes red blood cells to become misshapen and break down, leading to a range of complications. When a crisis occurs, management involves providing analgesia, rehydration, oxygen, and potentially antibiotics if there is evidence of infection. Blood transfusions may also be necessary, and in some cases, an exchange transfusion may be required if there are neurological complications.

In the longer term, prophylactic management of sickle-cell anaemia involves the use of hydroxyurea, which increases the levels of HbF to prevent painful episodes. Additionally, it is recommended that sickle-cell patients receive the pneumococcal polysaccharide vaccine every five years to reduce the risk of infection. By implementing these management strategies, individuals with sickle-cell anaemia can better manage their condition and improve their quality of life.

If symptoms appear after formula is introduced, it strongly indicates the presence of cow’s milk protein intolerance.

Cow’s milk protein intolerance/allergy (CMPI/CMPA) is a condition that affects approximately 3-6% of children and typically presents in formula-fed infants within the first 3 months of life. However, it can also occur in exclusively breastfed infants, although this is rare. Both immediate (IgE mediated) and delayed (non-IgE mediated) reactions can occur, with CMPA usually used to describe immediate reactions and CMPI for mild-moderate delayed reactions. Symptoms of CMPI/CMPA include regurgitation and vomiting, diarrhea, urticaria, atopic eczema, colic symptoms such as irritability and crying, wheezing, chronic cough, and rarely, angioedema and anaphylaxis.

Diagnosis of CMPI/CMPA is often based on clinical presentation, such as improvement with cow’s milk protein elimination. However, investigations such as skin prick/patch testing and total IgE and specific IgE (RAST) for cow’s milk protein may also be performed. If symptoms are severe, such as failure to thrive, referral to a pediatrician is necessary.

Management of CMPI/CMPA depends on whether the child is formula-fed or breastfed. For formula-fed infants with mild-moderate symptoms, extensively hydrolyzed formula (eHF) milk is the first-line replacement formula, while amino acid-based formula (AAF) is used for infants with severe CMPA or if there is no response to eHF. Around 10% of infants with CMPI/CMPA are also intolerant to soy milk. For breastfed infants, mothers should continue breastfeeding while eliminating cow’s milk protein from their diet. Calcium supplements may be prescribed to prevent deficiency while excluding dairy from the diet. When breastfeeding stops, eHF milk should be used until the child is at least 12 months old and for at least 6 months.

The prognosis for CMPI/CMPA is generally good, with most children eventually becoming milk tolerant. In children with IgE-mediated intolerance, around 55% will be milk tolerant by the age of 5 years, while in children with non-IgE mediated intolerance, most will be milk tolerant by the age of 3 years. However, a challenge is often performed in a hospital setting as anaphylaxis can occur.

When assessing a child’s constipation history and conducting an examination, certain red flags should be taken into consideration. If the child has been constipated since birth or within the first few weeks of life, or if there was a delay of more than 48 hours before passing meconium, it could indicate underlying conditions such as Hirschsprung’s disease or cystic fibrosis.

Additionally, the presence of multiple anal fissures or new neurological symptoms in the lower limbs should be cause for concern. If a large naevus is present over the sacral area, further investigation is necessary to rule out the possibility of spina bifida.

Understanding Constipation in Children

Constipation is a common problem in children, and its frequency varies with age. The National Institute for Health and Care Excellence (NICE) has provided guidelines for the diagnosis and management of constipation in children. A diagnosis of constipation is suggested by two or more symptoms, including infrequent bowel movements, hard stools, and symptoms associated with defecation. The vast majority of children have no identifiable cause, but other causes include dehydration, low-fiber diet, medications, anal fissure, over-enthusiastic potty training, hypothyroidism, Hirschsprung’s disease, hypercalcemia, and learning disabilities.

After making a diagnosis of constipation, NICE suggests excluding secondary causes. If no red or amber flags are present, a diagnosis of idiopathic constipation can be made. Prior to starting treatment, the child needs to be assessed for fecal impaction. NICE guidelines recommend using polyethylene glycol 3350 + electrolytes as the first-line treatment for faecal impaction. Maintenance therapy is also recommended, with adjustments to the starting dose.

It is important to note that dietary interventions alone should not be used as first-line treatment. Regular toileting and non-punitive behavioral interventions should also be considered. For infants not yet weaned, gentle abdominal massage and bicycling the infant’s legs can be helpful. For weaned infants, extra water, diluted fruit juice, and fruits can be offered, and lactulose can be added if necessary.

In conclusion, constipation in children can be effectively managed with proper diagnosis and treatment. It is important to follow NICE guidelines and consider the individual needs of each child. Parents can also seek support from Health Visitors or Paediatric Continence Advisors.

Understanding the Probability of Cystic Fibrosis Inheritance

Cystic fibrosis is an autosomal recessive condition that affects many individuals worldwide. The probability of inheriting this condition can be calculated based on the carrier status of the parents. Here are some examples of how to calculate the chance of having an affected child with cystic fibrosis:

1. 1 in 150: If one parent has a 2 in 3 chance of being a carrier and the other has a 1 in 25 chance, the overall chance of having an affected child is 1 in 150.

2. 1 in 10: If one parent has an affected sibling but is not affected themselves (2 in 3 chance of being a carrier), and the other parent has an unknown carrier status, the chance of having an affected child is 1 in 10.

3. 1 in 50: If one parent has a 2 in 3 chance of being a carrier and the other has a 1 in 25 chance, the chance of having an affected child is 1 in 4. Therefore, the overall chance is 2 in 3 x 1 in 25 x 1 in 4, which equals 1 in 50.

4. 1 in 100: If both parents are carriers (2 in 3 chance for one and 1 in 25 chance for the other), the chance of having an affected child is 1 in 4. Therefore, the overall chance is 2 in 3 x 1 in 25 x 1 in 4, which equals 1 in 100.

5. 1 in 200: The chance of being a carrier is not always 1 in 2, as it depends on the individual’s family history. If one parent has an affected relative but is not affected themselves (2 in 3 chance of being a carrier), the chance of having an affected child with a partner who has a 1 in 25 chance of being a carrier is 1 in 200.

Understanding the probability of cystic fibrosis inheritance can help individuals make informed decisions about family planning and genetic testing.

Testicular Lesions and Gynaecomastia in Young Males

This young male is presenting with tender gynaecomastia and a suspicious testicular lesion. The most likely diagnosis in this age group is a teratoma, as seminoma tends to be more common in older individuals. Gynaecomastia can be a presenting feature of testicular tumours, as the tumour may secrete betaHCG. Other tumour markers of teratoma include alphafetoprotein (AFP). It is important to note that testicular lymphoma typically presents in individuals over the age of 40 and is not associated with gynaecomastia. Early detection and treatment of testicular lesions is crucial for optimal outcomes.

NICE Guidelines for Referral of Suspected Colorectal Cancer

According to the National Institute for Health and Care Excellence (NICE) guidelines, individuals under the age of 50 who experience a change in bowel habit to looser and/or more frequent stools, along with rectal bleeding, should be urgently referred for suspected colorectal cancer.

In addition, NICE recommends considering a suspected cancer pathway referral for adults under 50 with rectal bleeding and unexplained symptoms such as abdominal pain, weight loss, and iron-deficiency anemia. These referrals should result in an appointment within two weeks to ensure prompt diagnosis and treatment.

It is important to follow these guidelines to ensure early detection and treatment of colorectal cancer, which can significantly improve outcomes for patients.

Systemic Methotrexate for Tubal Ectopic Pregnancy

According to RCOG Green top guideline No. 21, systemic methotrexate is a viable option for treating tubal ectopic pregnancy. This drug has been found to be equally successful as laparoscopic surgery in certain cases. However, it is crucial to first rule out an intrauterine pregnancy before administering methotrexate.

One advantage of using methotrexate is that it doesn’t affect ovarian reserve. However, women undergoing treatment should avoid alcohol and folate-containing vitamins. Additionally, it is recommended that women avoid pregnancy for at least three months after receiving methotrexate due to its teratogenic potential. This is because the drug may remain present in some organs for an extended period of time, which could potentially harm fetal development.

Treatment Options for Inflammatory Bowel Disease Exacerbations

Inflammatory bowel disease (IBD) can cause severe exacerbations that require hospitalization for fluid and electrolyte replacement, transfusion, and possibly intravenous corticosteroids. However, for less severe exacerbations of diffuse disease, there are other treatment options available.

One option is to increase the dose of mesalazine, which is an anti-inflammatory medication commonly used to treat IBD. Another option is to take oral prednisolone, which is a steroid medication that can help reduce inflammation in the gut.

For those with proctitis or distal disease, prednisolone enemas may be used as a treatment option. These enemas are administered directly into the rectum and can help reduce inflammation in the lower part of the colon.

Overall, the treatment options for IBD exacerbations depend on the severity and location of the disease. It is important to work closely with a healthcare provider to determine the best course of treatment for each individual case.

Treatment options for Urinary Urge Incontinence

Urinary urge incontinence is a common condition that can be treated with supervised bladder training for at least six weeks. This training can be provided by a continence nurse, physiotherapist, or urology clinic. If symptoms persist, an Antimuscarinic drug can be prescribed, with the lowest effective dose used and titrated upwards if necessary. It may take up to four weeks for the drug to take effect, and side effects such as dry mouth and constipation may occur. First-line drugs include oxybutynin, tolterodine, and darifenacin.

It is important to note that diuretics such as furosemide can potentially worsen symptoms of urinary urge incontinence. Amitriptyline is not recommended for this condition, as it is primarily used for depression, neuropathic pain, and migraine prophylaxis. Duloxetine may be used as a second-line treatment for stress incontinence, but it is not included in NICE guidelines for urinary urge incontinence. Desmopressin is typically used for other conditions such as diabetes insipidus, multiple sclerosis, enuresis, and bleeding disorders.

In summary, supervised bladder training and Antimuscarinic drugs are effective treatment options for urinary urge incontinence. It is important to consult with a healthcare professional to determine the best course of treatment for individual cases.

Patients who have acute severe hyponatraemia, which is defined as having a serum sodium concentration of less than 125 mmol/L, must be urgently hospitalized, as per the current NICE CKS guidelines. Therefore, referring the patient to a routine endocrinology clinic is not appropriate, as immediate action is necessary. Although diuretics like bendroflumethiazide can cause low sodium, it would be inappropriate to wait for 2 weeks before repeating the sodium levels. Similarly, ramipril can also cause low sodium, but waiting for 2 weeks before repeating the sodium level would be inappropriate, and urgent measures must be taken. Waiting for 2 weeks for repeat blood tests is not appropriate, and the patient should be admitted to the hospital due to the low level of serum sodium.

Understanding Hyponatraemia: Causes and Diagnosis

Hyponatraemia is a condition that can be caused by either an excess of water or a depletion of sodium in the body. However, it is important to note that there are also cases of pseudohyponatraemia, which can be caused by factors such as hyperlipidaemia or taking blood from a drip arm. To diagnose hyponatraemia, doctors often look at the levels of urinary sodium and osmolarity.

If the urinary sodium level is above 20 mmol/l, it may indicate sodium depletion due to renal loss or the use of diuretics such as thiazides or loop diuretics. Other possible causes include Addison’s disease or the diuretic stage of renal failure. On the other hand, if the patient is euvolaemic, it may be due to conditions such as SIADH (urine osmolality > 500 mmol/kg) or hypothyroidism.

If the urinary sodium level is below 20 mmol/l, it may indicate sodium depletion due to extra-renal loss caused by conditions such as diarrhoea, vomiting, sweating, burns, or adenoma of rectum. Alternatively, it may be due to water excess, which can cause the patient to be hypervolaemic and oedematous. This can be caused by conditions such as secondary hyperaldosteronism, nephrotic syndrome, IV dextrose, or psychogenic polydipsia.

In summary, hyponatraemia can be caused by a variety of factors, and it is important to diagnose the underlying cause in order to provide appropriate treatment. By looking at the levels of urinary sodium and osmolarity, doctors can determine the cause of hyponatraemia and provide the necessary interventions.

Management of QTc Prolongation in a Psychiatric Patient

It is important to seek advice from psychiatry before making any changes to medications in a psychiatric patient. Abruptly stopping an antipsychotic medication could lead to acute deterioration in the patient’s mental health.

When managing QTc prolongation, it is important to consider the normal values for QTc, which are < 440 ms in men and <470 ms in women. The degree to which the QTc is increased is relevant to the next step of management. If the QTc is >500 ms or there is abnormal T-wave morphology, it would require discussion with the on-call cardiology team and consideration of stopping the suspected causative drug(s).

Lithium would not typically be initiated by a general practitioner and would not be indicated in this case. Therefore, it is most appropriate to discuss with psychiatry for their advice. They may recommend lowering the antipsychotic dose and repeating the ECG. Proper management of QTc prolongation in a psychiatric patient requires collaboration between psychiatry and cardiology.